COLUMBUS, Ohio--(BUSINESS WIRE)--BioOhio, the state’s bioscience membership organization, is proud to announce the launch of its BioOhio30 campaign honoring the life changing work being done in Ohio to improve global quality of life, while also celebrating the release of the 2017 Ohio Bioscience Growth Report, and recognizing BioOhio’s 30th year in business.
The new report, released today by BioOhio, presents the strengths and assets of Ohio’s bioscience community, focusing on bioscience business and research occurring in Ohio and its six regions, including pharmaceuticals & therapeutics, medical devices, research & development, laboratories & imaging centers, digital health, agricultural biotechnology, bio-based materials & fuels, and their respective infrastructures. The report is available for download at BioOhio.com/Ohio.
Metrics covered in the Report, such as tracking of investment, average wages, research funding, expansions, and new company growth, serve as a gauge of the industry. However, beyond the numbers, the work being done by Ohio’s bioscience community is so much more important than any of these figures can convey.
Ohioans are curing debilitating pediatric diseases, creating less invasive surgical tools, formulating cleaner and more efficient biofuels, programming highly accurate diagnostic imaging techniques, improving provider processes to reduce patient costs, and personalizing medication delivery for individual patients.
In recognition of this important work, BioOhio is launching the #BioOhio30 social media campaign. With the support of long time BioOhio member Athersys, BioOhio30 will focus on the vast innovation in Ohio for the benefit of patients. BioOhio30 will consist of 30 posts over 30 days, each designed to highlight unique and meaningful patient stories and encourage other patients to share their own.
It is our goal that BioOhio30 will provide a library of stories that demonstrate Ohio’s climate of discovery and commitment to patients, and to achieving an increased nationwide appreciation of the diverse and groundbreaking research and development happening at local organizations. Visit BioOhio.com/Patients for a number of moving videos already available and follow BioOhio on Twitter, @BioOhio.
BioOhio is kicking off the campaign with a special video message from Solomon Wilcots, former Cincinnati Bengal and dedicated patient advocate, who will partner with the organization throughout BioOhio30.
2017 Ohio Bioscience Growth Report Highlights
Over 75,000 employees, the highest on record, work with at least 3,186 bioscience-related organizations, manufacturing products, providing essential services, or researching the next breakthrough at 3,994 facilities in Ohio, generating $5.68 billion of payroll at an average wage of $75,640.
The bioscience industry’s economic impact is felt throughout the state, with bioscience-related companies found in 81 of 88 Ohio counties. All six Ohio regions have experienced growth in the bioscience industry and play a role in advancing critical discoveries.
Ohio bioscience firms range from the large and well known such as Abbott, Battelle, Cardinal Health, Ethicon (a Johnson & Johnson company), Midmark, and STERIS, to young and growing companies including Abeona Therapeutics, AveXis, Genetesis, and Patients’ and Consumers’ Pharma.
Bioscience companies continue to expand, with over 9,000 projected new jobs and over $1 billion in capital investment announced in 2015-17. Alkermes, CoverMyMeds, ExactCare Pharmacy, IBM Watson Health, Medpace, Midmark, Nanofiber Solutions, Q Laboratories, Quality Electrodynamics, RelateCare, Sarnova, Sterigenics, and West-Ward Pharmaceuticals are all among the many companies that continue to grow in Ohio.
In the last five years, nearly 400 new bioscience-related firms began operations in Ohio. These include start-ups like Atumate, AveXis, Beyond Pulse Corp., Diasome Pharmaceuticals, Innovator Health, PriorAuthNow, RegenFix, Sujana Biotech, TearClear Technologies, Trailhead Biosystems, and Xact Medical. Also, many existing firms such as Aprecia Pharmaceuticals, Hikma Pharmaceuticals, Piping Rock Health Products, Pulse Flow Technologies, and Xellia Pharmaceuticals chose to locate their business in Ohio.
Ohio bioscience companies attracted over $2.17 billion in funding in 2016 from sources including venture capital, exits, angel investment, federal research grants, and state initiatives such as the Ohio Third Frontier. Companies received private investment worth $373 million in 2016 and tracking indicates at least $155 million invested so far in 2017. Exit activity in the state remained strong in 2016-17 with over $2 billion in acquisitions and a successful IPO by Medpace worth $173 million. Ohio bioscience research received $734 million from the National Institutes of Health in 2016.
Bioscience education continues to thrive in Ohio with 10,179 bioscience-related degrees and certificates awarded to students in Ohio in 2015 at 102 public and private schools.
Download the full report for in-depth discussion of these progress indicators and much more. BioOhio sincerely hopes you will join us in celebrating Ohio’s thriving bioscience community.
About BioOhio: BioOhio is a non-profit organization, founded in 1987, that connects and serves Ohio’s bioscience community to drive success in improving global quality of life by providing member-guided services that include networking, advocacy, events, talent, information, and cost savings. BioOhio represents over 300 members that employ over 100,000 Ohioans – from Ohio’s largest employers to emerging startups, schools & universities, research institutions, students, and individuals. BioOhio is the state affiliate for global bioscience associations AdvaMed, BIO, MDMA, and PhRMA. Learn more about BioOhio and its 2017 Membership Strategy at BioOhio.com/About.